-
Posted by
Two Blokes Jul 4 -
Filed in
Stock
-
5 views
Neurocrine's core assets, INGREZZA and Crenessity, can drive strong revenue growth with robust patent protection and significant market underpenetration. The pharma's pipeline is advancing, with multiple late-stage studies in major depressive disorder and schizophrenia offering substantial upside if successful. Competition remains a risk, but INGREZZA and Crenessity face limited near-term threats; pipeline assets could add billions in value if data is positive.
